Lataa...
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
OBJECTIVES: Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. METHODS: In this doub...
Tallennettuna:
| Julkaisussa: | Ann Rheum Dis |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4680140/ https://ncbi.nlm.nih.gov/pubmed/24951103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-205067 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|